On October 15, Argenx SE rose 3.26% in Pre-Market Trading, trading near $845.01, with turnover of $2.04 million. The move coincided with growing market focus on the company’s upcoming October 22 earnings release and relatively constructive expectations around the sales momentum and profit leverage of core product Vyvgart.
Available expectations indicate quarterly revenue is projected to rise 58.46% year over year, while consensus expects EPS of 7.44. In the prior quarter, Argenx SE reported revenue of $1.541 billion, up 59.33% year over year, gross margin of 59.05%, net income attributable to shareholders of $472 million, net margin of 30.63%, and adjusted EPS of $7.33, up 95.99%.
The recent backdrop also matters: after the company discontinued a phase 3 Sjogren’s disease study of subcutaneous efgartigimod for futility, sentiment appears to have stabilized as no new safety signals were identified, while FB102 posted a positive phase 2 result in celiac disease. Against that mix, the approaching earnings report has become a near-term support for the stock.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments